Japan myocardial infarction market is estimated to grow modestly at a CAGR of around 7.0% during the forecast period. The growth of the myocardial infarction market in Japan is being supported by innovative and advanced product launches by the key regional market players. The geriatric population is one of the major concerns for the Japanese government and other healthcare institutions in the country. As per the UN, out of the total 126 million population, about 27% population of the country was above 65 years in 2019. The possibility of a heart attack in the geriatric population is relatively high as compared to the young population. As per the Institute for Health Metrics and Evaluation, the country is witnessing a modest growth in the cases related to CVD. In 2014, 3.40 million new cases of CVD were witnessed in the country which was slightly increased to 3.54 million in 2017.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/japan-myocardial-infarction-market
The market is segmented into type, device, diagnosis, treatment, and end-user. Based on type, the market is segmented into ST-elevation myocardial infarction (STEMI) heart attacks, non-ST elevation myocardial infarction (NSTEMI) heart attacks, and silent heart attacks. Based on the device, the market is segmented into a left ventricular assist device, pacemaker, implantable cardioverter defibrillator, and others (aspiration-based catheters). Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest X-Ray, Computed Tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics, Ambulatory Surgical Centers (ASCs), and research institutes.
The companies which are contributing to the growth of the Japan myocardial infarction market include AstraZeneca PLC, Bayer AG, Abbott Laboratories Inc., GlaxoSmithKline PLC, Pfizer Inc., Koninklijke Philips N.V., Medtronic PLC, and Merck KGaA. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
A full report of Japan Myocardial Infarction Market available @ https://www.omrglobal.com/industry-reports/japan-myocardial-infarction-market
Japan Myocardial Infarction Market Segmentation
By Type
- Non-ST-elevation myocardial infarction (NSTEMI)
- ST-elevation myocardial infarction (STEMI)
- Silent Heart Attacks
By Device
- Left Ventricular Assist Device (LVAD)
- Pacemaker
- Catheters
- Implantable Cardioverter-Defibrillator (ICD)
- Others (Stent Graft)
By Diagnosis
- Electrocardiography (ECG)
- Chest X-Ray
- Computed Tomography (CT Scan)
- Echocardiography
- Others (Blood Test)
By Treatment
- Medication
- Analgesics
- Thrombolytic
- Antiplatelet Agents
- Glycoprotein IIb/IIIa Inhibitors
- Others (Beta-Adrenergic Blockers)
- Surgery
- Angioplasty
- Bypass Surgery
- Heart Transplant
By End-User
- Hospital & Clinics
- Ambulatory Surgical Centers
- Research Institutes
Company Profiles
- Abbott Laboratories Inc.
- AstraZeneca PLC
- Bayer AG
- Boston Scientific Corp.
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- GlaxoSmithKline Plc
- Johnson & Johnson Services, Inc.
- Medtronic PLC
- Merck KGaA
- Mylan N.V.
- Novartis AG
- Pfizer Inc.
- Siemens AG
